Recruiting

Sound waves and medication to treat recurring brain tumors

Plain-English translation of NCT06329570 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing whether combining (a medication that slows tumor growth) with a special ultrasound system called NaviFUS can safely and effectively treat glioblastoma that has returned after prior treatment. The ultrasound system uses sound waves and tiny bubbles to help the medication reach the tumor more effectively. The goal is to see if this combination approach works better than the medication alone.

When brain tumors come back after initial chemotherapy and radiation, treatment options become limited and outcomes are often poor. Researchers hope this new treatment strategy will help the medication penetrate the tumor more effectively and improve how well it works.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with glioblastoma that has come back after prior chemotherapy and radiation therapy
your tumor has either been mostly removed by surgery (at least 80%) or is small enough to measure
you are in good enough health to tolerate this treatment (a performance score of at least 70)
your blood work and organ function tests show you are healthy enough to participate
it has been at least 12 weeks since you finished radiation therapy and 4 weeks since chemotherapy

You likely don't qualify if…

you are pregnant or breastfeeding, or plan to become pregnant within 6 months after treatment
you have had major surgery within the past 4 weeks and have not fully recovered
your blood counts or kidney, liver, or heart function are too low or abnormal
your tumor is located too close to the outer surface of your brain (less than 30 mm beneath the skull)

What participation looks like

You will have a 2-week screening period to ensure you are eligible. Then you will come to the clinic every 2 weeks for up to 34 weeks to receive the treatment, which involves an intravenous infusion of the medication followed by an ultrasound procedure. Your doctor will monitor you closely with imaging scans and blood tests to see how you are responding and to watch for any side effects. Treatment will continue until your tumor progresses, you experience unacceptable side effects, or you have completed the full course.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Trial locations(1 site)

United States

University of Virginia, Charlottesville, Virginia